TREATMENT OF MASTOCYTOSIS WITH MASITINIB

摘要

The treatment of mastocytosis, and in particular indolent forms of mastocytosis (including smoldering systemic, indolent systemic and cutaneous mastocytosis), including administration of a tyrosine kinase inhibitor or a mast cell inhibitor, especially masitinib or a pharmaceutically acceptable salt or solvate thereof, in particular in an appropriate dosage regimen.

主权项

1. A method for treating severe systemic mastocytosis in human patients comprising administering a tyrosine kinase inhibitor or a pharmaceutically acceptable salt or solvate thereof, wherein said severe mastocytosis is associated with at least one mast cell mediator release associated handicap selected from the list comprising pruritus score ≧9; number of flushes per week ≧8; depression measured by the Hamilton rating scale ≧19 and fatigue score measured by Fatigue Impact Scale (FIS)≧75.